Prostate Cancer International is a
non-profit for 2012 as rated by Great NonProfits
The Surgical Prostatectomy versus Interstitial Radiation Intervention Trial or SPIRIT was a Phase III, partially randomized clinical trial, conducted in the U.S.A. and Canada, and designed to compare radical prostatectomy (RP) and brachytherapy (BT) as first-line treatments for men with localized prostate cancer. … READ MORE …
Filed under: Management, Treatment | Tagged: brachytherapy, HRQOL, localized, outcome, quality of life, radical prostatectomy, SPIRIT | Leave a Comment »
It has long been recognized that the combination of prostate cancer and diabetes tends to have a notable impact on the health-related quality of life (HRQoL) of male patients. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: diabetes, HRQOL, quality of life | Leave a Comment »
Data to be published in the May 2010 issue of the Journal of Urology are going to make a lot of urologists rather less than happy about the implications for the use of radical prostatectomy as first-line treatment for prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: brachytherapy, comparison, cryotherapy, HRQOL, outcome, quality of life, radical prostatectomy, RALP, RP | Leave a Comment »
Today’s news reports summarize papers recently published on:
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: "high risk", estradiol, hormone therapy, HRQOL, optimism, outcomes, paclitaxel, pessimism, quality of life, radiation, radical prostatectomy | Leave a Comment »
Having high socioeconomic status AND being in a strong, positive, and supportive relationship may have improved the health-related quality of life (HRQOL) of men with localized prostate cancer, according to a recent study. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: HRQOL, partners, quality of life | 1 Comment »
The decisions patients and their doctors make about which treatment to select as first-line therapy for localized prostate cancer are commonly based on perceptions and expectations about the side effects of these treatments, as well as on the curative potential of the therapy. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: comparison, first line, HRQOL, outcomes, quality of life, Treatment | Leave a Comment »
In today’s news reports we address:
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment, Uncategorized | Tagged: androgen receptor activity, brachytherapy, CRPC, dose, focal therapy, HRQOL, outcome, quality of life, signature, unilateral | Leave a Comment »
It is well known to readers of The “New” Prostate Cancer InfoLink that androgen deprivation therapy (ADT) is a commonly used form of treatment for patients who experience biochemical recurrence (BCR) after first- or second-line therapy. However, as is also well known, the optimal timing of ADT initiation is uncertain, and earlier initiation of ADT can cause toxicities that lower patients’ health-related quality of life (HRQOL). … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen deprivation therapy, anxiety, hormone therapy, HRQOL, quality of life | 3 Comments »
There are several news items again today. They deal with:
Filed under: Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: brachytherapy, continence, HRQOL, lymph node assessment, lymphadenectomy, mortality, protease-activated receptors, quality of life, radical prostatecftomy, serum calcium | Leave a Comment »
Today’s news report contains items on:
We have provided separate reports on the results of a clinical trial of flaxseed in men diagnosed with prostate cancer pre-treatment and on the 5-year outcomes of younger men treated with brachytherapy as first-line therapy for localized prostate cancer. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: chemohormonal therapy, HRQOL, mitochondrial genes, quality of life, spirituality, strontium-89, tumor size | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site